{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:52:44Z","timestamp":1781481164846,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"EDCPT","award":["SRIA2015-1061"],"award-info":[{"award-number":["SRIA2015-1061"]}]},{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"crossref","award":["SRIA2015-1061"],"award-info":[{"award-number":["SRIA2015-1061"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"crossref","award":["SRIA2015-1061"],"award-info":[{"award-number":["SRIA2015-1061"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"crossref","award":["SRIA2015-1061"],"award-info":[{"award-number":["SRIA2015-1061"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"crossref","award":["SRIA2015-1061"],"award-info":[{"award-number":["SRIA2015-1061"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI162151"],"award-info":[{"award-number":["R01AI162151"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI162151"],"award-info":[{"award-number":["R01AI162151"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-48746-2","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T02:33:09Z","timestamp":1776738789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetics of tenofovir alafenamide delivered via an annual subdermal implant in South African women"],"prefix":"10.1038","volume":"16","author":[{"given":"Martin","family":"Beliveau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marothi P.","family":"Letsoalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quarraisha Abdool","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S. Abdool","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanuja N.","family":"Gengiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc M.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"48746_CR1","unstructured":"UNAIDS. Fact Sheet 2024 - Global HIV Satistics. UNAIDS Geneva. (2024)."},{"key":"48746_CR2","unstructured":"UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS Epidemic. UNAIDS. (2014)."},{"key":"48746_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1128\/AAC.00597-11","volume":"56","author":"J Nuttall","year":"2012","unstructured":"Nuttall, J. et al. The pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Antimicrob. Agents Chemother. 56, 103\u2013109 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"48746_CR4","doi-asserted-by":"publisher","first-page":"e55013","DOI":"10.1371\/journal.pone.0055013","volume":"8","author":"CW Hendrix","year":"2013","unstructured":"Hendrix, C. W. et al. MTN-001: Randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One. 8, e55013 (2013).","journal-title":"PLoS One"},{"key":"48746_CR5","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1128\/AAC.04954-14","volume":"59","author":"JD Holt","year":"2015","unstructured":"Holt, J. D. et al. The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides. Antimicrob. Agents Chemother. 59, 3761\u20133770 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"48746_CR6","doi-asserted-by":"publisher","first-page":"35681","DOI":"10.1074\/jbc.M109.036616","volume":"284","author":"E Michailidis","year":"2009","unstructured":"Michailidis, E. et al. Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4 \u2018-Ethynyl-2-fluoro-2 \u2018-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor. J. Biol. Chem. 284, 35681\u201335691 (2009).","journal-title":"J. Biol. Chem."},{"key":"48746_CR7","doi-asserted-by":"publisher","first-page":"24533","DOI":"10.1074\/jbc.M114.562694","volume":"289","author":"E Michailidis","year":"2014","unstructured":"Michailidis, E. et al. 4 \u2018-Ethynyl-2-fluoro-2 \u2018-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms. J. Biol. Chem. 289, 24533\u201324548 (2014).","journal-title":"J. Biol. Chem."},{"key":"48746_CR8","doi-asserted-by":"crossref","unstructured":"Barrett, S. E. et al., Extended-duration MK-8591-eluting implant as a candidate for HIV treatment and prevention. Antimicrob Agents Chemother 62, (2018).","DOI":"10.1128\/AAC.01058-18"},{"key":"48746_CR9","doi-asserted-by":"publisher","unstructured":"Matthews, R. P. et al. Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial. Nat Med27(10) 1712\u20131717,https:\/\/doi.org\/10.1038\/s41591-021-01479-3 (2021).","DOI":"10.1038\/s41591-021-01479-3"},{"key":"48746_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/QAI.0000000000003135","volume":"92","author":"RP Matthews","year":"2023","unstructured":"Matthews, R. P. et al. Double-blind, placebo-controlled, phase 1 trial of radiopaque islatravir-eluting subdermal implants for pre-exposure prophylaxis against HIV-1 infection. J. Acquir. Immune Defic. Syndr. 92, 310\u2013316 (2023). A Randomized.","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"48746_CR11","unstructured":"Merck announces clinical holds on studies evaluating. Islatravir for the Treatment and Prevention of HIV-1 Infection (Merck & Co., Inc, 2021)."},{"key":"48746_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(25)00405-2","volume":"405","author":"V Jogiraju","year":"2025","unstructured":"Jogiraju, V. et al. Pharmacokinetics and Safety of Once-yearly Lenacapavir: A Phase 1, Open-label Study. Lancet 405, 1147\u20131154 (2025).","journal-title":"Lancet"},{"key":"48746_CR13","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1128\/AAC.00656-15","volume":"59","author":"M Gunawardana","year":"2015","unstructured":"Gunawardana, M. et al. Pharmacokinetics of Long-acting Tenofovir Alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob. Agents Chemother. 59, 3913\u20133919 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"48746_CR14","doi-asserted-by":"publisher","first-page":"11573","DOI":"10.1038\/s41598-024-58583-w","volume":"14","author":"N Akhavein","year":"2024","unstructured":"Akhavein, N. et al. Parenteral platforms for tunable, long-acting administration of a highly hydrophobic antiretroviral Drug. Sci. Rep. 14, 11573 (2024).","journal-title":"Sci. Rep."},{"key":"48746_CR15","doi-asserted-by":"publisher","first-page":"569373","DOI":"10.3389\/fphar.2020.569373","volume":"11","author":"M Gunawardana","year":"2020","unstructured":"Gunawardana, M. et al. Multispecies Evaluation of a Long-acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis. Front. Pharmacol. 11, 569373 (2020).","journal-title":"Front. Pharmacol."},{"key":"48746_CR16","doi-asserted-by":"publisher","unstructured":"Gunawardana, M. et al. Preclinical considerations for long-acting delivery of tenofovir alafenamide from subdermal implants for HIV Pre-exposure Prophylaxis. Pharm Res40(7) 1657\u20131672,https:\/\/doi.org\/10.1007\/s11095-022-03440-6 (2022).","DOI":"10.1007\/s11095-022-03440-6"},{"key":"48746_CR17","doi-asserted-by":"publisher","first-page":"8224","DOI":"10.1038\/s41598-022-11020-2","volume":"12","author":"M Gunawardana","year":"2022","unstructured":"Gunawardana, M. et al. Fundamental Aspects of Long-acting Tenofovir Alafenamide Delivery from Subdermal Implants for HIV Prophylaxis. Sci. Rep. 12, 8224 (2022).","journal-title":"Sci. Rep."},{"key":"48746_CR18","first-page":"e052880","volume":"6","author":"T Gengiah","year":"2021","unstructured":"Gengiah, T. et al. CAPRISA 018: A Phase I\/II Trial to Assess the Safety, Acceptability, Tolerability and Pharmacokinetics of a Sustained-release Tenofovir Alafenamide Sub-dermal Implant for HIV Prevention in Women. BMJ Open. 6, e052880 (2021).","journal-title":"BMJ Open."},{"key":"48746_CR19","doi-asserted-by":"publisher","unstructured":"Gengiah, T. N. et al. Safety, tolerability, and pharmacokinetics of an aannual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, First-in-human, Phase 1 Trial. Lancet HIV12(8),https:\/\/doi.org\/10.1016\/S2352-3018(25)00079-7 e556\u2013e567 (2025).","DOI":"10.1016\/S2352-3018(25)00079-7"},{"key":"48746_CR20","doi-asserted-by":"publisher","first-page":"e26426","DOI":"10.1002\/jia2.26426","volume":"28","author":"TN Gengiah","year":"2025","unstructured":"Gengiah, T. N. et al. Acceptability of an Annual Tenofovir Alafenamide Implant for HIV Prevention in South African Women: Findings from the CAPRISA 018 Phase I Clinical Trial. J. Int. AIDS Soc. 28, e26426 (2025).","journal-title":"J. Int. AIDS Soc."},{"key":"48746_CR21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/cpdd.1340","volume":"13","author":"X Ji","year":"2024","unstructured":"Ji, X., Li, Y., Wang, Z., Gao, Y. & Wang, L. Population pharmacokinetics of tenofovir alafenamide fumarate and its metabolite tenofovir in healthy chinese volunteers. Clin. Pharmacol. Drug Dev. 13, 168\u2013179 (2024).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"48746_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11095-009-0027-8","volume":"27","author":"E Soto","year":"2010","unstructured":"Soto, E., Haertter, S., Koenen-Bergmann, M., Staab, A. & Troc\u00f3niz, I. F. Population In Vitro-In Vivo Correlation Model for Pramipexole Slow-release Oral Formulations. Pharm. Res. 27, 340\u2013349 (2010).","journal-title":"Pharm. Res."},{"key":"48746_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz, R. J. et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl. J. Med. 385, 595\u2013608 (2021).","journal-title":"N Engl. J. Med."},{"key":"48746_CR24","doi-asserted-by":"crossref","unstructured":"Marzinke, M. A. et al. Characterization of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. J Infect. Dis224(9) 1581\u20131592, (2021).","DOI":"10.1093\/infdis\/jiab152"},{"key":"48746_CR25","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe, S. et al. Cabotegravir for the Prevention of HIV-1 in Women: Results from HPTN 084, a Phase 3, Randomised Clinical Trial. Lancet 399, 1779\u20131789 (2022).","journal-title":"Lancet"},{"key":"48746_CR26","unstructured":"FDA Approves First Injectable Treatment for HIV Pre-exposure Prevention. ). U.S. Food and Drug Administration (2021)."},{"key":"48746_CR27","unstructured":"Han, K. et al. Phase I study of cabotegravir long-acting injectable formulations supports\u2009\u2265\u20094-monthly dose interval. In: 2024 Conference on Retroviruses and Opportunistic Infections (CROI)). CROI, Alexandria, VA (2024)."},{"key":"48746_CR28","doi-asserted-by":"publisher","unstructured":"Bekker, L. G. et al., Twice-yearly Lenacapavir or Daily F\/TAF for HIV Prevention in Cisgender Women. N Engl. J. Med391(13), 1179\u20131192 https:\/\/doi.org\/10.1056\/NEJMoa2407001 (2024).","DOI":"10.1056\/NEJMoa2407001"},{"key":"48746_CR29","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.1128\/AAC.01152-15","volume":"59","author":"C Callebaut","year":"2015","unstructured":"Callebaut, C., Stepan, G., Tian, Y. & Miller, M. D. In Vitro virology profile of tenofovir alafenamide, a novel oral prodrug of tenofovir with improved antiviral activity compared to that of tenofovir disoproxil fumarate. Antimicrob. Agents Chemother. 59, 5909\u20135916 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"48746_CR30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1089\/aid.2021.0028","volume":"37","author":"JW Romano","year":"2021","unstructured":"RomanoJW et al. Tenofovir alafenamide for HIV prevention: review of the proceedings from the gates foundation long-acting TAF product development meeting. AIDS Res. Hum. Retroviruses. 37, 409\u2013420 (2021).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"48746_CR31","doi-asserted-by":"publisher","first-page":"e40382","DOI":"10.1371\/journal.pone.0040382","volume":"7","author":"S Duwal","year":"2012","unstructured":"Duwal, S., Sch\u00fctte, C. & von Kleist, M. Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic EEfficacy against HIV-1 Infection. PLoS One. 7, e40382 (2012).","journal-title":"PLoS One"},{"key":"48746_CR32","first-page":"e147","volume":"12","author":"K Madrasi","year":"2014","unstructured":"Madrasi, K., Burns, R. N., Hendrix, C. W., Fossler, M. J. & Chaturvedula, A. Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism. CPT Pharmacometrics Syst. Pharmacol Nov. 12, e147 (2014).","journal-title":"CPT Pharmacometrics Syst. Pharmacol Nov"},{"key":"48746_CR33","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/psp4.12955","volume":"12","author":"AN Kawuma","year":"2023","unstructured":"Kawuma, A. N. et al. Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population. CPT Pharmacometrics Syst. Pharmacol. 12, 821\u2013830 (2023).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"48746_CR34","unstructured":"Emtricitabine\/Tenofovir Alafenamide Fixed-dose Combination (FTC\/TAF [F\/TAF] FDC). In. 2.4 Nonclinical Overview (Gilead Sciences, Inc., 2022)."},{"key":"48746_CR35","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1592\/phco.23.6.695.32189","volume":"23","author":"BL Robbins","year":"2003","unstructured":"Robbins, B. L., Wilcox, C. K., Fridland, A. & Rodman, J. H. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 23, 695\u2013701 (2003).","journal-title":"Pharmacotherapy"},{"key":"48746_CR36","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","volume":"14","author":"WF Richter","year":"2012","unstructured":"Richter, W. F., Bhansali, S. G. & Morris, M. E. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 14, 559\u2013570 (2012).","journal-title":"AAPS J."},{"key":"48746_CR37","first-page":"526","volume":"29","author":"G Di Perri","year":"2021","unstructured":"Di Perri, G. Tenofovir Alafenamide (TAF) Clinical Pharmacology. Infez Med. 29, 526\u2013529 (2021).","journal-title":"Infez Med."},{"key":"48746_CR38","unstructured":"Highlights of Prescribing Information. DESCOVY\u00ae. (2022). https:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/hiv\/descovy\/descovy_pi.pdf Gilead Sciences, Inc., Foster City, CA."},{"key":"48746_CR39","doi-asserted-by":"publisher","first-page":"119210","DOI":"10.1016\/j.ijpharm.2020.119210","volume":"580","author":"MG Davan\u00e7o","year":"2020","unstructured":"Davan\u00e7o, M. G., Campos, D. R. & Carvalho, P. O. In vitro - in vivo correlation in the development of oral drug formulation: a screenshot of the last two decades. Int. J. Pharm. 580, 119210 (2020).","journal-title":"Int. J. Pharm."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48746-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48746-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48746-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:04:07Z","timestamp":1781478247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48746-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["48746"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-48746-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors Martin Beliveau and Colin Chang were employed by the company Certara Drug Development Solutions. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18424"}}